CJC-1295 DAC
Growth Hormone Releasing Peptide - Long-acting GHRH analog with drug-affinity complex.
CJC-1295 DAC incorporates a drug-affinity complex that extends its half-life, studied for sustained growth-hormone-axis stimulation in endocrine-research models.
The drug-affinity-complex version binds serum albumin to extend its presence, and research contrasts its sustained GHRH signalling against the more pulsatile no-DAC form. The half-life extension is itself a frequent subject of study.
CJC-1295 DAC specifications
- Sequence
- GHRH(1-29) analog with DAC
- Presentation
- Lyophilised powder
- Documented purity
- 99.46% by HPLC
- Available sizes
- 5mg ($60)
- Archived COA lots
- 2
- Intended use
- Laboratory research use only. Not for human or veterinary use.
Studied pathways
- Extended half-life - Albumin-binding complex studied for prolonged GHRH-receptor engagement.
Reported mechanisms in the literature
- Extended half-life - Incorporates a drug-affinity complex that binds serum albumin, studied for prolonged GHRH-receptor engagement and sustained GH-axis stimulation. (Teichman et al.)
CJC-1295 DAC frequently asked questions
What is CJC-1295 DAC?
A GHRH analog with a drug-affinity complex that extends its half-life, studied for sustained growth-hormone-axis stimulation.
Is it approved for human use?
No. It is a research material only, with preclinical data. It is not a medicine or supplement.
What does the DAC do?
The albumin-binding complex prolongs the compound's presence, which is the focus of its extended-half-life research.
Documented to 99.46% purity by HPLC · third-party COA every lot · from $60 · For laboratory research use only.
Related Growth Hormone compounds
- Tesamorelin - GHRH analog studied for growth-hormone-axis research.
- Ipamorelin - Selective GH secretagogue studied for receptor-selective GH release.
- CJC-1295 - GHRH analog studied for sustained GH signalling.